Glycopyrrolate + Indacaterol

Form: Inhalation powder delivered via Neohaler device/Breezhaler device

Strength: Ultibro Breezhaler: Indacaterol 85 mcg + Glycopyrronium 43 mcg

Reference Brands: Utibron Neohaler(Dis.cntd in US-2020); Ultibro Breezhaler(EU)

Category: Respiratory Disorder

Glycopyrrolate + Indacaterol is a dual bronchodilator combination used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), while Indacaterol is a long-acting beta2-agonist (LABA). Together, they provide effective, once-daily bronchodilation, improving lung function and reducing COPD symptoms like breathlessness. Marketed under brand names such as Ultibro Breezhaler in the EU and previously as Utibron Neohaler in the US, this inhalation therapy offers enhanced respiratory relief. It is not intended for acute symptom relief but plays a vital role in COPD management by optimizing airflow and improving patients’ quality of life.